Trevena ditches $86M IPO pitch; EU signs off on Roche's Kadcyla;

@FierceBiotech: Clovis bets up to $420M on targeted cancer drug. News | Follow @FierceBiotech

@JohnCFierce: Great talk with Missouri Bio and KansasBio today. About half read Fierce on their cell phones. New day and new media. | Follow @JohnCFierce

@DamianFierce: Meet Rebecca Friend, publisher of the FierceBiotech family of publications. More | Follow @DamianFierce

@EmilyMFierce: News about Art Levinson's Calico breaks on... Google+? Story | Follow @EmilyMFierce

> Trevena is the latest biotech hopeful to postpone plans for an IPO, pulling the plug on an $86 million offering. News

> Aeterna Zentaris ($AEZS) is raising $15.1 million in a stock sale to fund the development of AEZS-108, a breast and prostate cancer drug now in Phase II. More

> In one-year results, AMG 145, Amgen's ($AMGN) PCSK9 inhibitor, reduced LDL cholesterol by 52% compared to standard of care. Release

> The EU approved Roche's ($RHHBY) HER2-targeting cancer drug Kadcyla, which means another $5 million milestone for partner and antibody-drug conjugate mainstay ImmunoGen ($IMGN). Item

Medical Device News

@FierceMedDev: ResMed wins German court injunction against two respiratory device patent rivals. More | Follow @FierceMedDev

@MarkHFierce: J&J's $2.5B settlement addresses thousands of lawsuits over faulty metal hip implants but many will remain in play. Story | Follow @MarkHFierce

> Qiagen TB test gains Chinese regulatory approval. Article

> GenomeDx Biosciences seals multiple insurance deals for prostate cancer Dx. News

> Next Bard vaginal mesh trial set for December; settlement rumors remain. Report

Pharma News

@FiercePharma: Best-read new news Tuesday: Can Teva find a partner to save it from itself? Story | Follow @FiercePharma

@EricPFierce: GSK continues to lead with continuous processing. Will use technology at $136.5 million plant in India. More | Follow @EricPFierce

@CarlyHFierce: Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer. Release | Follow @CarlyHFierce

> Ex-Teva chief Jeremy Levin to MBA grads: Anyone have a job for me? Story

> Daiichi clot-fighter aces study, but can it compete with Pradaxa, Xarelto and Eliquis? Article

Drug Delivery News

@MichaelGFierce: Delivery guru Robert Langer discusses nanomeds, up-and-coming ventures, new frontiers. Editor's corner | Follow @MichaelGFierce

> Unilife signs $80M deal to supply Hikma with prefilled syringes. Story

> FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. Article

> Svelte begins pivotal trial for drug-eluting stent. Report

> Study: Genes delivered directly to heart stymie heart failure. More

> Dual-wave approach clears path for cancer drug delivery. Story

> Oramed wins European patent for insulin pill tech. Item

Diagnostics News

> GenapSys nails down $37M to advance next-generation gene sequencing tech. Article

> Trovagene pledges results, in part, from cancer urine test launch. Report

> Houston Methodist-led team shows potential of early breast cancer blood Dx. More

> Atossa makes headway in getting breast cancer test back to market. Article

> FDA OKs 4 Illumina next-generation sequencing devices. Report

> Johns Hopkins approach shows promise in early dementia diagnosis. Item

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.